Right now the U.S. Food and Drug Administration (FDA) is considering new regulatory requirements for automated external defibrillators (AEDs) that could significantly increase their cost and reduce public access to these proven, life-saving devices.  Even with the growing availability of AEDs in the U.S. and highly successful early defibrillation programs throughout the country, the current national SCA survival rate is less than 8%.  Actions that reduce public access to AEDs raise very serious public health concerns.

Now is the time to let FDA know that to save more lives from sudden cardiac arrest, we must continue to prioritize research, innovation, and widespread access to AEDs.